Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

MeSH terms

• Adolescent
• Adult
• Aminophenols* / therapeutic use
• Benzodioxoles* / therapeutic use
• Child
• Cystic Fibrosis Transmembrane Conductance Regulator
• Cystic Fibrosis* / drug therapy
• Cystic Fibrosis* / genetics
• Drug Combinations*
• Female
• Humans
• Indoles* / therapeutic use
• Male
• Pseudomonas Infections / drug therapy
• Pseudomonas Infections / microbiology
• Pyrazoles* / therapeutic use
• Pyridines / therapeutic use
• Pyrroles / therapeutic use
• Pyrrolidines
• Quinolines
• Quinolones* / therapeutic use